NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 15.98 against a street estimate of 12.50 — a beat of 27.8%.
with an average price target of ₹1,676.25.
| Holder | Stake |
|---|---|
| Quant Mutual Fund - Quant Small Cap Fund | 2.85% |
| Government Pension Fund Global | 2.33% |
| Massachusetts Institute of Technology | 1.23% |
| Old Bridge Focused Fund | 1.07% |
| Document | Date |
|---|---|
| Annual report FY2026 ALIVUS LIFE SCIENCES LIMITED – FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations: INR 25,518 Mn (up 6.9% YoY from INR 23, | 2026-08-11 |
| Q1 FY27 earnings call ALIVUS LIFE SCIENCES LIMITED – Q1 FY'27 SUMMARY HEADLINE NUMBERS • Revenue: INR 640 crores, up 6.4% year-on-year • Gross Profit: INR 385 crores, up | 2026-08-07 |
| Investor presentation ALIVUS LIFE SCIENCES LIMITED – Q1 FY27 INVESTOR PRESENTATION SUMMARY HEADLINE NUMBERS • Revenue Q1 FY27: ₹6,404 million, down 7.1% QoQ but up 6.4% Y | 2026-07-30 |
| Q4 FY26 earnings call ALIVUS LIFE SCIENCES LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 2,552 crores, +6.9% YoY growth • Q4 FY26 Revenue: INR 689 crores | 2026-05-21 |
| Investor presentation · Q4 FY26 ALIVUS LIFE SCIENCES LIMITED – Q4 FY26 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹25,518 Mn (+6.9% YoY); Q4FY26: ₹6,891 Mn (+6.1% YoY | 2026-05-14 |
| Quarterly results · Q4 FY26 ALIVUS LIFE SCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue: ₹25,518.32 million (up 6.9% YoY from ₹23,868.84 millio | 2026-05-14 |
| Q3 FY26 earnings call ALIVUS LIFE SCIENCES LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: Rs. 673 crores (14.4% QoQ, 4.8% YoY growth) • Q3 EBITDA: Rs. 24 | 2026-01-30 |
| Investor presentation · Q3 FY26 ALIVUS LIFE SCIENCES LIMITED – Q3 FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: ₹6,729 Million (14.4% QoQ growth, 4.8% YoY growth) • 9M | 2026-01-22 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Sep 1, 2026 | 2026-09-01 |
| Announcement | Date |
|---|---|
| Acquisition announced under Regulation 30 of SEBI LODR Alivus Life Sciences has acquired a 9.21% equity stake in Torrent Urja 19 Private Limited, a Torrent Green Energy subsidiary created to develop solar and other renewable-energy projects. Ali | 2026-10-07 |
| Acquisition of majority stake in IQGenX announced Alivus Life Sciences Limited announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited for INR 91.2 million (approximately $1.1 million USD). IQGenX, founded in 2016 | 2026-08-18 |
| Board approves acquisition of another business entity Alivus Life Sciences Limited approved acquiring a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 crores in an all-cash deal. IQGEN-X is a pharmaceutical company incorpor | 2026-08-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alivus Life Sciences Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.